Biotechnology company Alceus Bio has been awarded Pioneer Group and AbbVie’s 2025 Golden Ticket. 

The company, a developer of synthetic chimeric antigen receptor T-lymphocyte therapies for solid malignancies, was chosen as the winner after an extensive selection process. 

The Golden Ticket provides a significant package of support designed to accelerate the winner’s growth and development. Alceus Bio will now unlock opportunities including grant funding from AbbVie, 12 months rent-free incubation space at one of Pioneer’s facilities, and exclusive access to the Pioneer ecosystem. 

Alceus Bio will also receive tailored support from Pioneer’s Venture Development and Investment teams and AbbVie’s scientific and business executives, specialist business coaching from the Pioneer Expert Network, and opportunities to network with and learn from industry leaders. 

“We are honoured to be selected as winners of the Golden Ticket among so many outstanding applicants,” said Alexander Evans, Co-Founder and CEO of Alceus Bio. 

“This award offers Alceus an exceptional opportunity to access support and guidance from the teams at AbbVie and Pioneer.  

“We are excited to collaborate with both groups as we continue to advance our immune cell programming platform to unlock the full potential of AI-enabled peptide design.” 

Award is recognition of ‘vast potential’ of UK life sciences

The Golden Ticket initiative was designed to support breakthrough scientific discovery with the potential to advance human health and accelerate companies developing novel, transformational therapies and innovations for immunology, oncology, neurology, eye care, aesthetics, or other specialities including obesity, GI and hepatology. 

All applications were reviewed by the AbbVie and Pioneer Group selection committee, with shortlisted candidates invited to a pitching event. Alceus Bio was then selected as the winner of the 2025 initiative. 

Lord Vallance, Science Minister and Oxford-to-Cambridge Corridor Growth Champion, congratulated Alceus Bio, suggesting the triumph is important for the UK life sciences sector. 

“This win is recognition not just for their work [at Alceus Bio], but for the vast potential for so many of the UK’s life sciences innovators to build their ideas into thriving businesses and health breakthroughs. 

“It’s also a vote of confidence in the strength of Cambridge’s life sciences cluster – something which we want to propel to even greater heights, as an engine for growth for the entire nation.” 

 

Bruno Quinney, Content Team, DDW